If you are a student, recent graduate or alumni interested in exploring a career in the biotechnology, pharmaceutical and life sciences industries, you are in the right place! Register today to start your job search and be contacted by employers nationwide looking for you! It only takes a few minutes and you will be on your way to the perfect job!
Friday, February 19, 2010
The Obama administration’s new biofuels initiative is a much-needed step in federal coordination that can help pioneer companies secure the investment needed to build large-scale advanced biofuels production facilities. Rapid implementation of final Renewable Fuel Standard rules will create the market space for advanced biofuels; but more work is needed to accommodate further innovation and scale-up of new technologies. The Biotechnology Industry Organization (BIO) today thanked the Obama administration for renewing its commitment to support increased production and use of all biofuels, including advanced biofuels that can help create thousands of new green jobs, increase energy security and reduce greenhouse gas emissions.
Jim Greenwood, BIO president and CEO, stated, “The Obama administration clearly recognizes that large-scale production of advanced biofuels can be a driver of green job creation, energy security and greenhouse gas reductions. This new initiative will send a message to the industry and potential investors that the federal government is strongly committed to achieving advanced biofuels production and use targets. BIO has previously called for better federal coordination of programs to help integrate the complete biofuel supply chain, from crop production to fuel production and marketing. This coordination will help stimulate the private investment needed to build new biorefineries. On behalf of our member companies we thank the Obama administration for its leadership on this issue.Read Full Article
posted in: News, Washington DC
Tuesday, February 16, 2010
As the tough economy forces biotechs to halt projects or declare bankruptcy, the industry is looking to a provision in the Senate’s version of the healthcare reform bill to keep research going.
The so-called Therapeutic Tax Credit, backed by Sen. Robert Menendez (D-NJ), is intended to help companies with fewer than 250 employees pay the salaries of their scientists, continue research and even hire workers to help the companies develop new medicines, according to the Star Ledger.
The program would require companies to compete for money by submitting research projects to the federal Treasury Department. The companies would have to show how their projects lower healthcare costs or meet an unmet medical need. Tax credits will cover as much as 50 percent of the R&D expenses generated by the submitted project. The program is capped at $1 billion for the two-year period, according to the Ledger article.Read Full Article
posted in: News, Washington DC
Tuesday, December 22, 2009
The debate over healthcare reform is focused on such a small number of hot issues—should there be a public option, Medicare buy-in, government-paid mental health counseling for Sen. Lieberman?—that dozens of other questions are cruising under the radar.
Here’s one worth a lot more attention than it has been getting: Is Congress poised to make a big payoff to biotech firms and their venture backers by hindering the entry of a new class of generic drugs into the marketplace?Read Full Article
posted in: News, Washington DC
Monday, November 23, 2009
European researchers are on the cusp of overtaking their American counterparts in biotechnology innovation, especially when it comes to the development of cutting-edge medicines known as “biologics.” These medicines are grown in living cells and consist of molecules thousands of times bigger than those in conventional drugs.
In 2004, European biotech firms had access to only 20% of the private equity financing that U.S. firms had. Today the European Union has just about as many dedicated biotechnology firms as the U.S., according to OECD figures.
Yet just as the European biotech industry’s substantial investments in research and development—about a third of revenues in recent years—is beginning to pay off, U.S. policy makers are considering legislation that would hamstring biotech research in their own country. This would provide a welcome boost to Europe’s biopharmaceutical sector but hurt the U.S. industry and overall scientific progress.Read Full Article
posted in: News, Washington DC
Wednesday, October 21, 2009
Washington, D.C. - Today, the House of Representatives passed the conference report for the Agriculture, Rural Development, Food and Drug Administration Appropriations Act which provides funding for the United States Department of Agriculture (USDA), the Food and Drug Administration (FDA) and related agencies for the upcoming fiscal year. This legislation includes $2.963 million requested by Rep. Herseth Sandlin for important agriculture-related projects in South Dakota, listed below. This legislation also provides $2.25 million in funding for the Sun Grant Initiative, administered by SDSU, which was authorized as a federal program through the Farm Bill passed last year. The Sun Grant Initiative conducts important research that holds tremendous potential to improve the domestic supply of renewable energy.
The bill was passed by the House in July and the Senate in August, and differences in the two versions were worked out in a conference committee. Following House passage, it is anticipated that the Senate will agree to the conference report and send it to the President for his signature.
“South Dakota State University is leading the way in conducting vital research that benefits farmers and ranchers across the country and supports our country’s efforts to diversify its energy economy,” Rep. Herseth Sandlin said. “I’m proud to once again support these projects and look forward to continuing my work with SDSU to advance these priorities that hold so much potential for our state’s rural community and the country as a whole.“Read Full Article
posted in: News, South Dakota, Washington DC
Monday, October 19, 2009
The Biotechnology Industry Organization (BIO) announced today that it is accepting nominations for the second annual Biotech Humanitarian Award. The Award will be given to an individual who, through their work in or support of biotechnology, has begun to harness its potential heal, fuel or feed the planet.
“Every day, biotech innovators work hard to unlock solutions to global issues,” said Jim Greenwood, president and CEO of BIO. “Through the Biotech Humanitarian Award, we can spotlight their efforts to demonstrate biotech’s vital role in helping heal, fuel and feed the world.“Read Full Article
posted in: News, Washington DC
Monday, October 12, 2009
For three days, representatives from the Colorado BioScience Association
(CBSA),Colorado Office of Economic Development and International Trade, Metro
Denver Economic Development Corporation and the Greater Colorado Springs
Economic Development Corporation will be showcasing Colorado`s medical device
and diagnostics sectors during the annual AdvaMed: The MedTech Conference. The
announcement is made by John Collar, CBSA Executive Director, who says more than
1,400 industry leaders - including 500+ CEOs, Presidents and C-level executives
will be attending the AdvaMed: The MedTech Conference, October 12-14.
“This will be the CBSA`s third year participating in the AdvaMed Conference and
each year the potential connections and opportunity to showcase Colorado`s
medical device and diagnostics industries becomes even more abundant,” said
Collar. “According to our new state of the industry report, the Denver Metro
region ranks 19th among all U.S. metro areas in the size of our medical device
sector, and Boulder, Colorado ranks first in the nation in its concentration of
employment in the medical device sector among medium-sized metros. Colorado is
positioned as a leader in this sector and this conference provides us an
opportunity to promote the state.“Read Full Article
posted in: Colorado , News, Washington DC
Tuesday, September 29, 2009
Washington, D.C. (U.S. GC Release) The U.S. Grains Council and the Iowa Corn Promotion Board have sent out an invitation to the press to attend a unique opportunity to meet biotechnology regulators from Latin America and Central America at the U.S. Grains Council’s 2009 International Biotechnology Information Conference (IBIC). The international participants will be taking a tour of an Iowa corn farm and you are encouraged to attend.
Prior to the farm visit, the IBIC program includes meetings in Washington, D.C., with CropLife International; National Corn Growers Association; Biotechnology Industry Organization; International Food Information Council; International Life Sciences Institute; USDA’S Animal & Plant Health Inspection Service; Food and Drug Administration; and Environmental Protection Agency. Following these meetings focused on current U.S. regulatory processes and progression in the biotechnology field, the participants will travel to Des Moines, Iowa, for a one-day seminar at Iowa State University, a visit to a grain elevator and meetings with Pioneer, A DuPont Business; Syngenta; and Monsanto Company, focused on the regulatory process, product registration and approval of stacked biotech events.Read Full Article
posted in: Iowa, News, Washington DC
Monday, September 28, 2009
Washington, D.C. (U.S. GC Release) The U.S. Grains Council and the Iowa Corn Promotion Board have sent out an invitation to the press to attend a unique opportunity to meet biotechnology regulators from Latin America and Central America at the U.S. Grains Council’s 2009 International Biotechnology Information Conference (IBIC). The international participants will be taking a tour of an Iowa corn farm and you are encouraged to attend.
Prior to the farm visit, the IBIC program includes meetings in Washington, D.C., with CropLife International; National Corn Growers Association; Biotechnology Industry Organization; International Food Information Council; International Life Sciences Institute; USDA’S Animal & Plant Health Inspection Service; Food and Drug Administration; and Environmental Protection Agency. Following these meetings focused on current U.S. regulatory processes and progression in the biotechnology field, the participants will travel to Des Moines, Iowa, for a one-day seminar at Iowa State University, a visit to a grain elevator and meetings with Pioneer, A DuPont Business; Syngenta; and Monsanto Company, focused on the regulatory process, product registration and approval of stacked biotech events.Read Full Article
posted in: Iowa, News, Washington DC
Sunday, September 20, 2009
You can’t open a newspaper today without reading about the need for health care reform. Costs are skyrocketing, and people are demanding access to high quality care and new medicines. How can a system balance the need to reduce costs with the desire for new therapies? .
Advertisement
Some of our local policymakers are looking to biologics as part of the answer. Biologics are medicines made from living cells that treat debilitating diseases such as cancer, HIV/AIDs, Alzheimer’s disease and multiple sclerosis. Because the cutting-edge technology used to create biologics is far more complex than the process used to manufacture chemical-based drugs like aspirin, there is currently no regulatory pathway for approving “biosimilars,” or medicines that are similar to, but not the same as innovator biologics.Read Full Article
posted in: News, Washington DC
Phoenix • Tucson • Palm Springs • Sacramento • San Diego • San Francisco • San Jose • Denver • Jacksonville • Miami • Orlando • Tampa • Atlanta • Chicago • Indianapolis • Kansas City • Louisville • New Orleans • Boston • Baltimore • Detroit • Grand Rapids • Minneapolis • Charlotte • Raleigh • Omaha • Atlantic City • Las Vegas • Reno • Buffalo • New York City • Cincinnati • Cleveland • Toledo • Tulsa • Portland • Philadelphia • Pittsburgh • Myrtle Beach • Memphis • Nashville • Austin • Dallas • Houston • San Antonio • Salt Lake City • Richmond • Seattle • Spokane
